Bayer using Accenture’s AI tool to accelerate drug development
Accenture Life Sciences, a technology consulting firm, announced that its artificial intelligence (AI) clinical data collection and management tool, Intient, is being used by Bayer.
The platform, which went live at Bayer earlier this year, uses cloud-based technology developed by Oracle to enable the collection of internal and external clinical data into a single data management and storage platform.
As a result, Intient has the potential to create actionable insights to accelerate drug development and improve patient outcomes.
Under the collaboration agreement between Bayer and Accenture, the former company has also joined the Life Sciences Cloud Coalition, a group of businesses built by Accenture and Oracle, to link biopharmaceutical companies willing to share their clinical data.
A spokesperson for Accenture told us “With the addition of Bayer, we have already seen a resounding commitment to collaboration with their peers in industry.”
“Bayer brings a global, patient-centric approach to their clinical development processes and have been transparent in their sharing of processes and best practices,” the spokesperson added.
Members of the Life Sciences Cloud Coalition include Pfizer, Eli Lilly, Bayer, Merck, Novo Nordisk and GlaxoSmithKline.
The aim of the coalition, according to Accenture, is to enable ‘pre-competitive’ collaboration between companies and support quick and cost-effective advancement of clinical development.
“The future of R&D is bright when leading organizations come together to solve for patients’ greatest needs,” commented Mike Stapleton, a managing director in Accenture’s Life Sciences practice.
